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There Are Miles to Go Before We Sleep*Peter P. Toth, MD, PHDT he treatment of dyslipidemia with statintherapy is a cornerstone in the managementof patients in both the primary and second-
ary prevention settings. Dyslipidemia is widely prev-
alent in its various forms (1). The lowering of
low-density lipoprotein cholesterol (LDL-C) with a
statin in patients with established coronary heart dis-
ease (CHD) has shown unequivocal capacity to safely
reduce risk for clinical sequelae such as nonfatal
myocardial infarction, ischemic stroke, cardiovascu-
lar and all-cause mortality, as well as the need for
revascularization (2,3). The American College of Car-
diology/American Heart Association Guideline for
the Treatment of Blood Cholesterol continues to place
primary emphasis on cardiovascular (CV) risk reduc-
tion by lowering LDL-C by a speciﬁc percentage ac-
cording to estimated level of risk for sustaining an
acute CV event (4).
Statin therapy generally lowers risk for an acute CV
event by 25% to 45% over 5 years of follow-up,
depending upon the magnitude of LDL-C reduction,
speciﬁc patient characteristics, and the intensity of
statin therapy used. Consistent with these ﬁndings,
the “residual risk” for a CV event is estimated as
being 55% to 75%. Clearly, not all of the residual
risk is attributable to dyslipidemia. Persistent ciga-
rette smoking, inadequately controlled hypertension,*Editorials published in the Journal of the American College of Cardiology
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Guest Editor for this paper.obesity, insulin resistance, and other risk factors all
contribute. However, because elevated triglycerides
and non-high-density lipoprotein cholesterol (HDL-C)
and low HDL-C have also been shown to be inde-
pendent risk factors for CV events, there has been
understandable motivation to address this residual
risk with use of adjuvant lipid-modifying therapies
that provide incremental LDL-C lowering, tri-
glycerides and non-HDL-C reduction, and HDL-C
elevation.
The treatment of elderly patients ($65 years of age)
is an issue that is often met with some trepidation.
Questions arise as to the strength of evidence sup-
porting lipid lowering in older patients. The decision
to treat may also be inﬂuenced by age-related im-
pairments in renal and hepatic function, reduced
muscle mass and frailty, risk of drug interactions
secondary to substantial polypharmacy, and neuro-
cognitive integrity. Contrapuntal to these concerns is
the fact that elderly patients are at highest CV risk
and hence are among the most vulnerable for sus-
taining both primary and secondary coronary and
cerebrovascular events. The HPS (Heart Protection
Study) (5) and the PROSPER (Pravastatin in Elderly
Individuals at Risk of Vascular Disease) (6) studies
randomized 10,697 patients $65 years of age and
5,804 patients who are 70 to 82 years of age, respec-
tively, to treatment with either statin or placebo. In
HPS, the elderly patients derived as much CV beneﬁt
from simvastatin therapy as their younger counter-
parts. In PROSPER, pravastatin signiﬁcantly reduced
the risk for the primary composite endpoint as well as
for multiple individual endpoints including a 24%
decrease in cardiovascular mortality. An important
meta-analysis which included elderly patients from 9
large prospective randomized controlled trials
showed that statin therapy for an average of 5 years
was associated with the following reductions in CV
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1874endpoints: 22% all-cause mortality (number needed to
treat [NNT]: 22), 30% CV mortality (NNT: 34), 26%
nonfatal myocardial infarction (NNT: 3), 30% coronary
revascularization via coronary artery bypass grafting
or percutaneous stenting (NNT: 30), and 25% stroke
(NNT: 58) (7). Such ﬁndings certainly support the use
of statin therapy in older patients with established
CHD.
More recently, other studies lend further support
to the use of statins in elderly patients. The Age, Gene/
Environment Susceptibility-Reykjavik Study included
5,152 men and women with a mean age of 77 years
(range 66 to 96 years) and compared CV and all-cause
mortality among patients who did and did not receive
statin treatment over a median follow-up period of
5.3 years (8). Among persons with diabetes mellitus
(DM), statin therapy reduced CV and all-cause mor-
tality by 50% and 53%, respectively. For persons
without DM, statin therapy reduced CV and all-cause
mortality by 16% and 30%, respectively. In the Jeru-
salem Longitudinal Cohort Study compared to no
treatment, statin therapy was associated with signiﬁ-
cant increases in survival among those 78 to 85 years of
age (74.7% vs. 64.3%, log-rank p ¼ 0.07) and 85 to 90
years of age (76.2% vs. 67.4%; p ¼ 0.01) (9). Both of
these studies were observational and nonrandomized
and must, therefore, be interpreted with caution.
However, they clearly emphasize the beneﬁt of statin
therapy in elderly patients.SEE PAGE 1864In this issue of the Journal, Bittner et al. (10) explore
the use of lipid-lowering medications in more than
300,000 elderly patients with established CHD using a
cohort from a Medicare database. Over the 5-year
period of surveillance, statin usage among these pa-
tients increased from 53.1% to 58.8%. This is a positive
ﬁnding, but it still constitutes inadequate treatment.
Approximately 40% of elderly patients with CHD are
not receiving a therapy known to reduce recurrent CV
events, disability, and death. Certainly some patients
do not tolerate statins because of myalgia and other
side effects (11). But such a high prevalence of high-risk
patients not being treated with a statin is puzzling.
There was also a small increase in the percentage of
these patients treated with high-intensity statin, hav-
ing increased from 11.1% to 14.2%. This too is inade-
quate. Age alone should not determine treatmentwith,
or intensity of, a statin. High-intensity statin therapy is
known to reduce event rates better than lower in-
tensity statin therapy (3). The current guideline en-
courages the use of high-intensity statin therapy in
elderly patients unless the treating physician ascer-
tains they are not an appropriate candidate in whichcase they are encouraged to treat with moderate-
intensity statin therapy (4).
These investigators also explored the usage
patterns of nonstatin lipid-modifying medications.
The ﬁndings are of great interest. Subsequent to pub-
lication of the ENHANCE (Ezetimibe and Simvastatin
in Hypercholesterolemia Enhances Atherosclerosis
Regression) trial, there was a steep reduction in the
prescribing of ezetimibe of two-thirds in patients on
statin therapy and approximately 50% among patients
not taking a statin (12). ENHANCE evaluated the efﬁ-
cacy of adding ezetimibe to statin therapy in patients
with heterozygous familial hypercholesterolemia.
Given ﬂaws in the design of the study and the thin
carotid intima media thickness at baseline (0.69 mm),
the result was predictable (13). There was no apparent
increase in prescribing when the SANDS (Stop
Atherosclerosis in Native Diabetics Study) trial sug-
gested that ezetimibe used in combination with a
statin had a positive impact on rates of carotid intima
media thickness progression (14). The prescribing of
ezetimibe likely declined further when the Simva-
statin and Ezetimibe in Aortic Stenosis (SEAS) trial
suggested an increased signal for malignancy (15),
despite a subsequent meta-analysis which suggested
no such relationship existed (16). With publication of
the IMPROVE-IT (IMProved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial), we now have ev-
idence that the addition of ezetimibe to statin therapy
is safe and provides a degree of risk reduction that is
commensurate with themagnitude of LDL-C reduction
in patients who have sustained an acute coronary
syndrome (17). Understandably, it is anticipated that
the use of ezetimibewill gradually increase in response
to these ﬁndings. A very interesting ﬁnding is that,
despite having evidence for reducing cardiovascular
events (18), bile acid binding resin therapy did not in-
crease as ezetimibe use decreased.
In contrast to prescribing patterns with ezetimibe,
publication of the negative ACCORD (Action to Con-
trol Cardiovascular Risk in Diabetes) trial had little to
no effect on the prescribing of fenoﬁbrate (19). The
reason for this is not immediately obvious especially
because the FIELD (Fenoﬁbrate Intervention and
Event Lowering in Diabetes) trial was also negative
(20). When the AIM-HIGH (Atherothrombosis Inter-
vention in Metabolic Syndrome with Low HDL/High
Triglycerides: Impact on Global Health Outcomes)
trial was discontinued due to futility (21), there was
an apparent small decrease in the prescribing of
niacin, a ﬁnding that is more intuitively obvious. This
will likely trend further down because publication of
HPS-2 THRIVE (Heart Protection Study-2: Treatment
of HDL to Reduce the Incidence of Vascular Events)
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1875also showed no efﬁcacy attributable to niacin adju-
vant therapy (22).
These authors found additional important relation-
ships. Male sex and Caucasian race compared to
female sex and other racial groups were associated
with a higher likelihood of being prescribed nonstatin
adjuvant therapy, possibly signaling a disparity in
care. Having DM increases risk for mixed forms of
dyslipidemia, and diabetic patients had a higher rate
of being prescribed adjuvant therapy.
There is much yet to be learned about residual
risk and the role of adjuvant lipid-lowering therapy.However, as this study makes clear, the prescribing of
lipid-loweringmedication by health care providers and
its responsiveness to clinical trials is an issue that
warrants much careful additional study. In the mean-
time, it is crucial that statins and adjuvant therapies
with demonstrable efﬁcacy be used appropriately to
helpmore patients achieve guideline-determined goals
for LDL-C reduction, especially among elderly patients.
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